Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01059578 | First Study in Humans With GSK206136 | PHASE1 | COMPLETED | 33 | — | — | May 23, 2006 | Dec 18, 2006 | Aug 10, 2017 | 1 | United Kingdom |
| Arm | Type | Description |
|---|---|---|
| Active | EXPERIMENTAL | GSK206136 once daily |
| Placebo | PLACEBO_COMPARATOR | Placebo once daily |
| Name | Type | Description |
|---|---|---|
| GSK206136 | DRUG | GSK206136 2mg, 10mg, 50mg, 100mg capsule |
| PLACEBO | DRUG | Placebo to match 206136 2mg, 10mg, 50mg, 100mg capsule |
| PET | RADIATION | Each subject will undergo 3 PET Scans ; one at Baseline and the others following dosing with GSK206136 at approximately 2 hours post-dose and 24 hours post-dose |
Inclusion Criteria: * Healthy males aged 18-45 years, limited to 25-40 years of age for PET section Exclusion Criteria: * The subject has a positive: drug/alcohol, Hepatitis, HIV screen.. * The subject has a history of psychiatric illness suicidal attempts or behaviour. * Abuse of alcohol. * Clin...